The Fourth Central Hospital of Tianjin Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial
2017
NCT03309501
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

The Fourth Central Hospital of Tianjin | Tianjin 4th Centre Hospital

Active Ingredients

Drugs in Phase 4 Trials (2)

oseltamivir (tamiflu) (1 trial)

reduning (1 trial)

Drugs in Phase 3 Trials (2)

qi-zheng-xiao-tong (1 trial)

tong-luo-qu-tong (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Influenza, Human (Phase 4)

Musculoskeletal Diseases (Phase 3)

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 4